The Prevalence of Immediate Hypersensitivity Reactions to the BNT162b2 mRNA Vaccine against SARS-CoV-2: Data from the Vaccination Campaign in a Large Academic Hospital

The Prevalence of Immediate Hypersensitivity Reactions to the BNT162b2 mRNA Vaccine against SARS-CoV-2: Data from the Vaccination Campaign in a Large Academic Hospital

The anti-SARS-CoV-2 vaccination has probably been the most effective tool for preventing the infection and negative outcomes of the COVID-19 disease, and therefore for interrupting the pandemic state. The first licensed SARS-CoV-2 vaccine was BNT162b2, an mRNA vaccine that has been widely used since...

Full description

Bibliographic Details
Main Authors: Giovanni Paoletti, Jack Pepys, Maria Chiara Bragato, Sandro Paoletti, Alessandra Piona, Maria Rita Messina, Francesca Racca, Sebastian Ferri, Emanuele Nappi, Giovanni Costanzo, Lorenzo Del Moro, Francesca Puggioni, Giorgio Walter Canonica, Elena Azzolini, Enrico Heffler
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Vaccines
Subjects:
SARS-CoV-2
COVID-19
vaccine
allergy
hypersensitivity
Online Access:https://www.mdpi.com/2076-393X/11/5/903

Internet

https://www.mdpi.com/2076-393X/11/5/903

Similar Items